News

Lessons learned from an ongoing retinal implant program at the University of Southern California are being applied to the development of a novel refillable and programmable drug delivery device that could be used in glaucoma management.

These days, we in the medical profession are devoting considerable attention to fashion.

Jeffrey B. Kindler, chief executive officer and chairman of the board of Pfizer Inc., received the Glaucoma Research Foundation (GRF) Catalyst Award at the organization's annual benefit and celebration.

Ophthalmologists, ophthalmic organizations, and companies operating in the ophthalmology arena are contributing to efforts to help Haiti respond to and recover from the earthquake that occurred in January.

Fera Pharmaceuticals is now shipping erythromycin and bacitracin ophthalmic ointments.

Intrastromal corneal ring segments can improve visual and refractive outcomes in eyes with keratoconus by reshaping the cornea, but collagen crosslinking may have an additive effect as an enhancement and stabilizing procedure.

All current IOL options for presbyopia correction involve some compromise, according to one ophthalmologist.

A unique fusion protein is being studied to treat age-related macular degeneration, diabetic macular edema, and macular edema secondary to central retinal vein occlusion.

The time at which an IOL is implanted following ocular trauma can be controversial.

The Wilmer Eye Institute at Johns Hopkins University School of Medicine, Baltimore, may be based near the nation's capital but, since its earliest days, the institute has considered its primary mission to improve eye care throughout the world.

Changes in the profession are on the horizon. There is a need to increase ophthalmic capacity to deal with the aging American population, among other needs specific to the profession.

The adoption of electronic medical records in the United States has been slow, but interest seems to be picking up despite a number of obstacles.

Use of IOLs during first year of life remains controversial. Currently, implanting IOLs in infants is an off-label use of these lenses.

The combinations of verteporfin photodynamic therapy (PDT), ranibizumab, and dexamethasone and verteporfin PDT and ranibizumab for treating patients with choroidal neovascularization secondary to age-related macular degeneration resulted in fewere re-treatments compared with ranibizumab alone in the phase II exploratory RADICAL study, according to one investigator.

Pazopanib, an investigational topical therapy for age-related macular degeneration (AMD), showed positive beneficial results for treating choroidal neovascularization in a phase IIa trial.

"Bean Town," a unique blend of modern sophistication and historic New England charm, will host the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) from April 9 to 14.

Results of a retrospective study evaluating safety of LASIK flap creation using the 60-kHz femtosecond laser show complications occur at a low overall incidence and, ultimately, are visually insignificant, according to one researcher.

Recognition and treatment of meibomian gland dysfunction and dry eye disease are important in contact lens wearers because these common conditions are a frequent cause of lens intolerance.

Bepostastine besilate ophthalmic solution 1.5% (Bepreve, ISTA Pharmaceuticals) is safe and well-tolerated in healthy children as young as 3 years of age, according to results from a multicenter, prospective, double-masked, randomized, placebo-controlled trial.

Blink Tears Lubricating Eye Drops improved dry eye symptoms significantly better than Systane Lubricant Eye Drops when the artificial tears were paired with topical cyclosporine ophthalmic emulsion.

In the future, a range of devices will be available to restore corneal integrity and function.

A 1-mg dose of intravitreal triamcinolone had a safety profile superior to that of a 4-mg dose of intravitreal triamcinolone and produced visual acuity increases similar to the 4-mg groupand better than the standard-of-care group, according to the primary outcomes of a randomized clinical trial.

For patients who are suffering with moderate to severe signs and symptoms of seasonal or perennial allergic conjunctivitis, loteprednol etabonate ophthalmic suspension 0.2% (Alrex, Bausch & Lomb) is a safe and well-tolerated therapeutic option that can provide rapid clinical improvement, according to new research.

Former first lady Laura Bush stressed the importance of good vision care at the Inaugural Kids Vision Fest, presented by the Essilor Vision Foundation and the Kids Vision for Life Coalition.

An efficacy evaluation comparing two marketed artificial tears showed that a polyethylene-based product (Systane Ultra, Alcon Laboratories) resulted in statisically greater reductions in corneal and conjunctival staining than a glycerin/carboxymethylcellulose-based tear (Refresh Optive, Allergan).

The overall anti-allergic eye drop market consists of about 25 products developed and approved in the United States (with some marketed abroad) to address the needs of the seasonal allergic conjunctivitis patient population.

International Vision Expo and Conference East promises to deliver all the latest products, trends, and information on medical eye care, fashion, lens technology, and business solutions at its annual meeting here.

Just a few weeks after announcing a controversial plan to take over ophthalmic giant Alcon Laboratories, Novartis announced its chief executive officer is stepping down and the chief financial officer will retire.